Jean-Jacques Kiladjian, MD, PhD from Saint-Louis Hospital & Paris Diderot University, Paris, France discusses a selection of topics covered during the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Dr Kiladjian outlines presentations on myeloproliferative neoplasms, specifically essential thrombocythemia (ET) and the PT-1 trial, and polycythemia vera (PV). In talks regarding treatment of PV it was discussed how ruxolitinib could lessen the JAK2 mutant allele burden.
What’s new in myeloproliferative neoplasms?
